Composition for Treating Cirrhosis and Liver Cancer (SB-1121)

• Status: Completed
• Trial end date: 2021-11-10
• Target enrollment: 0
• Participant gender: All

Summary

The composition treats cirrhosis and hepatocellular carcinoma (Hcc) at an early stage. The product is extracted from herbs, including Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Ascorbic acid, pyridoxine 5-phosphate, L-Arginine hydrochloride, Pregnenolone acetate. These components have participated in repairing and regenerating new liver parenchyma, preventing fibrosis cell generation, preventing liver cancer cell growth at an early stage. The composition supplements precursors which help the body strengthen antibodies and reduce the risk of inflammation, restore physiological and biochemical functions of liver cells after chronic inflammation.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Nguyen Thi Trieu, MD

Criteria

Inclusion Criteria:

• All patients with underlying medical conditions who have been taking medications for these conditions.

• Patients with AIDS, HIV, HBV, HCV, and patients with co-infections.

• The cancer patients are stable.

• Patients with congenital or acquired immunodeficiency.

Exclusion Criteria:

• Unstable cancer patients.

• Decompensated cirrhosis.